Edithistory:Cevostamab
From EverybodyWiki Bios & Wiki
| oldid | date/time | username | edit summary |
|---|---|---|---|
| 1361894876 | 2026-06-30T18:41:44Z | Kowal2701 | [[WP:LLMPRV|Presumptive removal of LLM-generated content]], see [[Wikipedia:AI noticeboard/Archive 2#LLM edits by Noxoug1]]. Feel free to reinstate by following [[WP:LLMPRVOBJ|the procedures for disputing presumptive removal of LLM-generated content]]. |
| 1314036522 | 2025-09-29T11:08:27Z | Monkbot | [[User:Monkbot/task 21: Replace page(s) with article-number|Monkbot/task 21: Replace page(s) with article-number]]; |
| 1310281159 | 2025-09-08T18:17:10Z | Tassedethe | Disambiguate [[BCMA]] to [[B-cell maturation antigen]] using [[:en:Wikipedia:Tools/Navigation_popups|popups]] |
| 1310280845 | 2025-09-08T18:14:48Z | Tassedethe | |
| 1309546926 | 2025-09-04T18:25:14Z | Innerstream | |
| 1309485999 | 2025-09-04T10:09:31Z | Noxoug1 | |
| 1307126614 | 2025-08-21T18:03:09Z | Pichpich | +[[Category:Multiple myeloma]]; +[[Category:Experimental monoclonal antibodies]]; +[[Category:Cancer immunotherapy]] using [[WP:HC|HotCat]] |
| 1307058347 | 2025-08-21T08:14:28Z | Folkezoft | General fixes via [[Wikipedia:AutoWikiBrowser|AutoWikiBrowser]], added [[CAT:O|orphan]], [[CAT:UNCAT|uncategorised]] tags |
| 1307053916 | 2025-08-21T07:26:21Z | Noxoug1 | infobox |
| 1307053305 | 2025-08-21T07:19:12Z | Noxoug1 | /* Clinical development */ |
| 1307051298 | 2025-08-21T07:07:51Z | Noxoug1 | ce |
| 1306988329 | 2025-08-20T21:34:39Z | Citation bot | Added doi. | [[:en:WP:UCB|Use this bot]]. [[:en:WP:DBUG|Report bugs]]. | Suggested by Graeme Bartlett | #UCB_toolbar |
| 1306948149 | 2025-08-20T16:38:45Z | Boghog | consistent citation formatting |
| 1306929190 | 2025-08-20T14:17:09Z | Noxoug1 | Rescuing 7 sources and tagging 0 as dead.) #IABot (v2.0.9.5 |
| 1306929075 | 2025-08-20T14:15:57Z | Citation bot | Added doi-broken-date. | [[:en:WP:UCB|Use this bot]]. [[:en:WP:DBUG|Report bugs]]. | Suggested by Noxoug1 | #UCB_webform |
| 1306928981 | 2025-08-20T14:15:07Z | Noxoug1 | |
| 1306928491 | 2025-08-20T14:10:59Z | Noxoug1 | |
| 1306928356 | 2025-08-20T14:09:47Z | Noxoug1 | see also |
| 1306928291 | 2025-08-20T14:09:20Z | Noxoug1 | Regulatory status |
| 1306928198 | 2025-08-20T14:08:35Z | Noxoug1 | |
| 1306928134 | 2025-08-20T14:08:05Z | Noxoug1 | Administration |
| 1306928056 | 2025-08-20T14:07:24Z | Noxoug1 | Target population |
| 1306927905 | 2025-08-20T14:06:25Z | Noxoug1 | Safety profile |
| 1306927850 | 2025-08-20T14:05:56Z | Noxoug1 | /* Phase II studies */ |
| 1306927779 | 2025-08-20T14:05:24Z | Noxoug1 | /* Phase II studies */ CAMMA 1 study |
| 1306927736 | 2025-08-20T14:05:00Z | Noxoug1 | Phase II studies |
| 1306927674 | 2025-08-20T14:04:29Z | Noxoug1 | Phase I studies |
| 1306927614 | 2025-08-20T14:03:51Z | Noxoug1 | /* Mechanism of action */ |
| 1306927533 | 2025-08-20T14:03:17Z | Noxoug1 | /* Mechanism of action */ |
| 1306927495 | 2025-08-20T14:02:49Z | Noxoug1 | mechanism of action |
| 1306927445 | 2025-08-20T14:02:21Z | Noxoug1 | |
| 1306927341 | 2025-08-20T14:01:24Z | Noxoug1 | infobox |
| 1306927232 | 2025-08-20T14:00:31Z | Noxoug1 | intro |
| 1306927072 | 2025-08-20T13:59:23Z | Noxoug1 | create article |
